Arrowhead to participate in Chardan Genetic Medicines Conference
Arrowhead reports inducement grants
Shares of Arrowhead Pharmaceuticals (NASDAQ: ARWR) are up by 49.9% as of 11:35 a.m. EDT on Wednesday, after rising by as much as 51.1% earlier today. Investors are bidding up shares of the biopharmaceutical company today following the release of interim data from a phase 2 clinical trial for one of its pipeline candidates, ARO-AAT. Arrowhead Pharma is developing ARO-AAT as a treatment for liver disease associated with alpha-1 antitrypsin deficiency (AATD).